Pier Capital LLC Has $5.13 Million Holdings in Olema Pharmaceuticals, Inc. $OLMA

Pier Capital LLC trimmed its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 32.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 524,249 shares of the company’s stock after selling 246,823 shares during the period. Pier Capital LLC owned approximately 0.76% of Olema Pharmaceuticals worth $5,132,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Ameritas Investment Partners Inc. increased its stake in shares of Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock valued at $26,000 after acquiring an additional 2,168 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Olema Pharmaceuticals during the third quarter worth $53,000. American Century Companies Inc. bought a new position in Olema Pharmaceuticals during the second quarter worth $54,000. Police & Firemen s Retirement System of New Jersey grew its holdings in Olema Pharmaceuticals by 76.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 14,195 shares of the company’s stock worth $60,000 after purchasing an additional 6,141 shares during the period. Finally, ProShare Advisors LLC grew its holdings in Olema Pharmaceuticals by 21.1% in the second quarter. ProShare Advisors LLC now owns 14,766 shares of the company’s stock worth $63,000 after purchasing an additional 2,569 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Insider Activity at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 10,000 shares of Olema Pharmaceuticals stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total transaction of $268,800.00. Following the completion of the transaction, the director owned 727,770 shares in the company, valued at approximately $19,562,457.60. The trade was a 1.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Naseem Zojwalla sold 99,509 shares of Olema Pharmaceuticals stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $27.66, for a total value of $2,752,418.94. Following the transaction, the insider owned 4,488 shares of the company’s stock, valued at $124,138.08. This trade represents a 95.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 805,501 shares of company stock valued at $23,003,832 over the last quarter. 16.36% of the stock is currently owned by company insiders.

Olema Pharmaceuticals Stock Performance

OLMA opened at $14.91 on Friday. Olema Pharmaceuticals, Inc. has a 1-year low of $2.86 and a 1-year high of $36.26. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -7.97 and a beta of 1.92. The company’s fifty day moving average price is $24.39 and its two-hundred day moving average price is $18.34. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Citigroup lifted their price target on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, December 12th. HC Wainwright cut their price objective on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating on the stock in a research report on Monday. Stifel Nicolaus initiated coverage on Olema Pharmaceuticals in a research note on Wednesday, February 11th. They issued a “buy” rating and a $48.00 target price for the company. JPMorgan Chase & Co. boosted their target price on Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, UBS Group began coverage on Olema Pharmaceuticals in a research note on Wednesday, January 7th. They set a “buy” rating and a $45.00 price target on the stock. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.00.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.